LOPEZ DE DIEGO; Heidi

Patent Applications and Registrations

Patent applications and USPTO patent grants for LOPEZ DE DIEGO; Heidi.The latest application filed is for "crystalline forms of a magl inhibitor".

Company Profile

2.19.25

LOPEZ DE DIEGO; Heidi - N.ae butted.rum DK
Lopez de Diego; Heidi - Naerum DK
Lopez De Diego; Heidi - Narum DK
Lopez de Diego, Heidi - Kokkedal DK

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Crystalline Forms Of A Magl Inhibitor App 20210147367 - GRICE; Cheryl A. ; et al.	2021-05-20
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine As A Compound With Combined Serotonin Reuptake, 5-ht3 And 5-ht1a Activity Fo App 20200163959 - Faldt; Andre ; et al.	2020-05-28
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine As A Compound With Combined Serotonin Reuptake, 5-ht3 And 5-ht1a Activity For The Treatment Of Cognitive Impairment App 20180333408 - Faldt; Andre ; et al.	2018-11-22
Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine Grant 10,034,876 - Treppendahl , et al. July 31, 2	2018-07-31
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment Grant 9,861,630 - Faldt , et al. January 9, 2	2018-01-09
1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT App 20170360777 - Faldt; Andre ; et al.	2017-12-21
Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine App 20170224677 - Treppendahl; Svend ; et al.	2017-08-10
Crystalline Forms Of 4-[2-(4-methylphenylsulfanyl)-phenyl] Piperidine App 20170037006 - Bang-Andersen; Benny ; et al.	2017-02-09
Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine Grant 9,475,748 - Treppendahl , et al. October 25, 2	2016-10-25
Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine Grant 9,315,459 - Bang-Andersen , et al. April 19, 2	2016-04-19
1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT App 20160083359 - Bang-Andersen; Benny ; et al.	2016-03-24
Liquid Formulations Of Salts Of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine App 20150094316 - Treppendahl; Svend ; et al.	2015-04-02
Crystalline Forms Of 4-[2-(4-methylphenylsulfanyl)-phenyl] Piperidine App 20150073018 - Bang-Andersen; Benny ; et al.	2015-03-12
Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine Grant 8,940,746 - Treppendahl , et al. January 27, 2	2015-01-27
Nalmefene hydrochloride dihydrate Grant 8,754,217 - Lopez de Diego , et al. June 17, 2	2014-06-17
Crystalline forms of a pharmaceutical compound Grant 8,729,065 - Rock , et al. May 20, 2	2014-05-20
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment Grant 8,722,684 - Bang-Andersen , et al. May 13, 2	2014-05-13
Nalmefene Hydrochloride Dihydrate App 20130338365 - Lopez de DIEGO; Heidi ; et al.	2013-12-19
Nalmefene hydrochloride dihydrate Grant 8,530,495 - Lopez de Diego , et al. September 10, 2	2013-09-10
Crystalline Forms Of 4-[2-(4-methylphenylsulfanyl)-phenyl] Piperidine With Combined Serotonin And Norepinephrine Reuptake Inhibition For The Treatment Of Neuropathic Pain App 20130190352 - Bang-Andersen; Benny ; et al.	2013-07-25
Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine Grant 8,450,324 - Bang-Andersen , et al. May 28, 2	2013-05-28
Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition and uses thereof Grant 8,299,095 - Bang-Andersen , et al. October 30, 2	2012-10-30
Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide App 20120165325 - Treppendahl; Svend ; et al.	2012-06-28
Liquid Formulations Of Salts Of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine App 20120035188 - Treppendahl; Svend ; et al.	2012-02-09
Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine App 20120004409 - Nicolajsen; Henrik Vigan ; et al.	2012-01-05
Malonate salt of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and uses of same Grant 8,076,342 - Lopez de Diego , et al. December 13, 2	2011-12-13
Nalmefene Hydrochloride Dihydrate App 20110251228 - Lopez de Diego; Heidi ; et al.	2011-10-13
Crystalline Forms of a Pharmaceutical Compound App 20110124629 - Rock; Michael Harold ; et al.	2011-05-26
Malonate Salt Of 4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine And Uses Of Same App 20110053957 - Lopez de Diego; Heidi ; et al.	2011-03-03
Processes For 4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine Or A Salt Thereof App 20100324291 - Lopez de Diego; Heidi ; et al.	2010-12-23
1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] Piperazine As A Compound With Combined Serotonin Reuptake, 5-ht3 And 5-ht1a Activity For The Treatment Of Cognitive Impairment App 20100297240 - Bang-Andersen; Benny ; et al.	2010-11-25
Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide App 20100286138 - Treppendahl; Svend ; et al.	2010-11-11
Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament Grant 7,767,683 - Lopez de Diego , et al. August 3, 2	2010-08-03
Crystalline Base Of Trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine App 20100105699 - Bang-Andersen; Benny ; et al.	2010-04-29
Tartrate and Malate Salts of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine App 20080269248 - Nielsen; Ole ; et al.	2008-10-30
Crystalline forms of a pharmaceutical compound App 20070191339 - Rock; Michael Harold ; et al.	2007-08-16
1'-[4-[1-(4-fluorophenyl)-1H-indole-3-Y1]-spiro[isobenzofuran-1(3H), 4'-piperidine]hydrohalogenides App 20050171135 - Mork, Niels ; et al.	2005-08-04
1'-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H ),4'-piperidine] hydrohalogenides Grant 6,844,352 - M.o slashed.rk , et al. January 18, 2	2005-01-18
1'-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3- H),4'-piperidine] hydrohalogenides App 20030055074 - Mork, Niels ; et al.	2003-03-20

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.